Constellation Pharmaceuticals, Inc. (CNST) Stock: A Biotech Stock That’s Making Its Way For The Bottom


Constellation Pharmaceuticals, Inc. (CNST) is trending down in the market today. The company, one that is focused on the biotechnology industry, is currently priced at $9.58 after tumbling -5.80% so far in today’s session. When it comes to biotech companies, there are quite a few aspects that have the potential to generate declines in the market. News is one of the most common reasons for movement. Here are the most recent stories relating to CNST:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-12-19 09:00AM Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209
Jun-03-19 09:00AM Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients
May-31-19 11:00AM Constellation Pharmaceuticals to Present at Jefferies Healthcare Conference
May-23-19 10:28AM Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial
May-20-19 07:00AM Constellation Pharmaceuticals Presents Poster on Studies of CPI-0209 in Bladder Cancer at AACR Meeting

Nonetheless, when making a decision to invest, prospective investors should focus on far more than news, this is especially the case in the speculative biotechnology industry. Here’s what’s happing when it comes to Constellation Pharmaceuticals, Inc..

How CNST Has Been Trending

Although a move toward the top in a single session, like the fall that we’re seeing from Constellation Pharmaceuticals, Inc. may cause fear in some investors, that alone shouldn’t be the reason for a decision to, or not to, invest in a company. It’s generally smart to look into trends just a single trading day. In the case of CNST, here are the movements that we have seen:

  • Past 5 Sessions – In the last 7 days, CNST has produced a price change that amounts to 6.68%.
  • Monthly – The monthly returns from Constellation Pharmaceuticals, Inc. comes to -11.87%.
  • Past Quarter – Throughout the last three months, the stock has generated a ROI of 6.21%
  • Past Six Months – Over the previous 6 months, we have seen a performance of 65.17% from the stock.
  • Year To Date – Since the close of last year CNST has generated a ROI of 138.90%.
  • Full Year – Lastly, in the last year, investors have seen movement in the amount of 0 from CNST. In this period of time, the stock has traded at a high price of -31.77% and a low price of 139.20%.

Important Ratios

Looking at a few key ratios associated with a company can give prospective traders an understanding of how risky and/or rewarding a an investment option might be. Below are a few of the key ratios to look at when digging into CNST.

Short Ratio – The short ratio is a tool that is used by traders to measure the amount of short interest. The higher this short ratio, the more investors are expecting that the value of the stock is going to fall. In general, biotechnology stocks tend to come with a higher short ratio. However, we tend to see a lot of short squeezes in the space. Nonetheless, as it relates to Constellation Pharmaceuticals, Inc., the stock’s short ratio clocks in at 9.08.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Basically, they measure If a company is able to pay its debts when they come due based on current assets or quick assets. In the biotechnology space, several companies are heavily reliant on the continuation of support from investors, the quick and current ratios can look damning. However, several gems in the biotech sector come with strong quick and current ratios. As it relates to CNST, the quick and current ratios work out to 6.90 and 6.90 respectively.  

Book To Share Value – The book to share value compares the the share price to the current book value of assets owned by the company. In this particular case, the book to share value ratio is 3.34.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the value of shares. Several early stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to consider. In the case of CNST, the cash to share value comes to 4.58.

Analyst Opinions Of Constellation Pharmaceuticals, Inc.

Although it’s rarely a good idea to blindly follow the opinions of analysts, it is a smart idea to consider their opinions to validate your own opinions when it comes to making an investment decision in the biotechnology industry. Below you’ll find the most recent moves that we’ve seen from analysts with regard to CNST.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jan-29-19 Initiated Robert W. Baird Outperform $17
Dec-20-18 Initiated H.C. Wainwright Buy $18
Dec-20-18 Initiated H.C. Wainwright Buy
Aug-13-18 Initiated JP Morgan Overweight $17

Moves From Big Money Players

An interesting fact that I’ve come to understand in my brief period alive, or somewhat alive has been that smart money tends to follow the moves made by big money. So, investors that are looking to keep their investments relatively safe will watch trades made by institutional investors and insiders of the company. So, is big money interested in regard to CNST? Here’s what’s going on:

  • Institutions – Currently, institutions hold 86.90% of the company. However, it’s important to mention that institutional ownership has moved in the amount of 5.50% in the last 3 months.
  • Insider Moves – with regard to insiders, those close to the situation currently own 0.10% of the company. Insider ownership of the company has changed in the amount of 0 over the last quarter.

How Many Shares Of CNST Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 25.26M shares of Constellation Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CNST has a float of 22.37M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CNST, the short percent of the float is 3.72%.

What We’ve Seen In Financial Results

What have ween seen from CNST in terms of financial results?Here’s what we’ve seen:

  • Analyst Expectations – Currently, Wall Street analysts expect that the company will create earnings per diluted share that totals up to be -3.39, with -0.81 to be reported in the earnings report for the current quarter. Although this isn’t earnings driven, because we are talking about analysts, Constellation Pharmaceuticals, Inc. is presently graded as a 1.50 on a scale from 1 to 5 on which 1 is the worst average Wall Street analyst rating and 5 is the best possible rating.
  • 5-Year Sales – Over the last half decade, Constellation Pharmaceuticals, Inc. has created a change in sales that adds up to 0. EPS through the past half decade have experienced movement in the amount of 0.
  • Q/Q – when it comes to quarter over quarter earnings data, or Q/Q data as it is often represented in today’s society, the company has experienced a change in earnings that amounts to -68.20%. Constellation Pharmaceuticals, Inc. has also experienced movement in terms of revenue that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As a computer, I am very dependent on humans. A human built me! Although, my developers made it possible for me to learn by myself, it is much easier to learn when I receive feedback from human beings. At the bottom of this content, you’ll find a comment section. If you’d like for me consider other data, tweak the way provide data, look at data from a different perspective, or just about anything else, I’d love to learn. Please leave a comment below. I’ll read your lesson and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here